Navigation Links
Human guinea pigs wary of high-paying medical trials
Date:12/4/2009

  • More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participation.

  • Research institutions view payments to volunteers as compensation for time and expenses; not as compensation for potential risks related to participating in the experiments.

  • A new study finds that volunteers have a very different view of clinical trial compensation. High-paying research studies raise a red flag for human guinea pigs and signal high levels of risk.

The findings from a study published this month by the journal Social Science and Medicine have implications for informed consent in human subjects research and the debate over research participation incentives.

Cynthia Cryder, assistant professor of Marketing at the Olin Business School, Washington University in St. Louis, is the lead author of the study, "Informative Inducement: Study Payment as a Signal of Risk"*. Her co-authors are Alex John London and George Loewenstein at Carnegie Mellon University and Kevin G. Volpp at the University of Pennsylvania School of Medicine and the Wharton School.

"At a big-picture level, what stands out from these results is that research participants do not just consider participation payments as an incentive to be traded off for their time." Cryder explains. "They actually infer information about the study itself from the participation payment."

Cryder and colleagues conducted three experiments to measure people's interest in participating in potentially risky research studies, their perception of the risk associated with those studies and how payment amounts affected their interest and perceptions.

Experiments for the study were conducted with an online nationwide sample or a sample from a northeastern U.S. city in 2007-2008.

The study finds that while high
'/>"/>

Contact: Melody Walker
melody_walker@wustl.edu
314-935-5202
Washington University in St. Louis
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Humana Launches Dancetown on Tues., Dec. 8 in Kissimmee
2. The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH
3. The therapeutic benefits of the human-animal bond
4. Bono and Wyclef Jean Receive RFK Center for Justice & Human Rights Ripple of Hope Award
5. Coal Pollution Damages Human Health at Every Stage of Coal Life Cycle, Reports Physicians for Social Responsibility
6. Human Pheromone Sciences Announces Third Quarter Results
7. Physicians for Human Rights Offers Training in Crime Scene Documentation
8. NIAID announces new human immunology research awards to help fight emerging infectious diseases
9. Not What the Doctor Ordered: Rapid Environmental Change Threatens the Foundations of Human Health
10. Precuneus region of human and monkey brain is divided into 4 distinct regions
11. NovaBays Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 Cuidado Casero ... and hospice, PCO, PCA, and PHC in Texas, New Mexico, ... a sponsor of the North Texas Chapter of PAM’s 2014 ... the Peruvian American Medical Society. The North Texas chapter was ... and other professionals interested in improving medical care for the ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
(Date:7/27/2014)... Detroit, MI (PRWEB) July 27, 2014 ... the public with organic ways to achieve a younger ... eye cream buyer's guide to help men and women ... . , The details that are presented in the ... range of price information for consumers. On drawback to ...
(Date:7/27/2014)... new pill-only antiviral drug regimens could provide shorter, more ... majority of patients infected with hepatitis C, even those ... two studies published in The Lancet . , ... is the most common genotype in the USA, Europe, ... the most difficult to treat. , Around 150 million ...
(Date:7/27/2014)... a powerful drug given at the time of a ... of rejection, but that it also allows a less ... the operation. , The key results are reported in ... Transplant Congress in San Francisco today. They will help ... combinations of treatments used to prevent early kidney rejection ...
Breaking Medicine News(10 mins):Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3
... cause damage to the brain of youngsters, says a ... misuse can do to them. // ,Thomas Heffernan, ... students for the research presented at the British Psychological ... of Daily Mail. ,Half the students ...
... research team from the New York University College of Dentistry ... oral decay evolved along with its human hosts. ... common ancestor who lived in Africa between 100,000 and 200,000 ... by Page Caufield, a professor of cariology and comprehensive care ...
... in EMBO says that the parasite that is responsible ... new pathway. Sleeping sickness is caused by Trypanosoma brucei ... ,Shulamit Michaeli and colleagues describe a pathway in T. ... this pathway shuts down the synthesis of a crucial ...
... the healthcare sector with a super-specialty hospital in Gurgaon,// on ... of Rs.2.1 billion ($45 million). ,Christened Artemis Health ... will open next month. "In the second phase, another 240 ... of AHS. ,"This is the first of similar ...
... governments to join the anti-tuberculosis global plan, which would ... disease has become extremely drug-resistant. ,Ban's message ... on Saturday. The World Health Organization (WHO) recently reported ... of tuberculosis, XDR-TB, which threatens to derail efforts to ...
... be hampered if they indulge in excessive drinking.// This ... a psychologist from Northumbria University. ,Alcohol and ... young age which could extend into adulthood. According to ... a very crucial stage. ,Dr. Thomas Heffernan ...
Cached Medicine News:Health News:Tooth Decay Bacteria Evolved Along With Man 2
(Date:7/28/2014)... Germany and LONDON , ... , Collaboration aims to create and commercialize companion diagnostic ... use of IRESSA  for non-small cell lung cancer patients  ... FDA-approved  therascreen   EGFR test and is planned to run on Rotor-Gene ... Project enabled by AstraZeneca master framework agreement ...
(Date:7/25/2014)... July 25, 2014  In today,s marketplace, launching multiple ... challenging - as is managing a portfolio of products ... it possible - or even preferable - to pool ... can you combine resources and activities, and what marketing ... These are just a few of the dilemmas facing ...
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- Full Service CRO ... new Vice President of Business Development. Peter has been ... a number of different business development positions with some ... were primarily related to business development/sales management and marketing.  ... years makes him a key and strategic asset to ...
Breaking Medicine Technology:QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2
... FALLS, N.J., Dec. 22, 2010 Regenicin, Inc. (OTC Bulletin ... the development of regenerative cell therapies to restore the health ... Annual OneMedForum on January 11-13, 2011 in San Francisco. Randall ... and business model for bringing new regenerative medicine products to ...
... MiMedx Group, Inc. (OTC Bulletin Board: ... patent protected biomaterial-based products, announced today that it has ... leader in the development of tissue processing techniques for ... amnion membranes. Privately held Surgical Biologics was ...
Cached Medicine Technology:Regenicin CEO to Present at OneMedForum Business Development and Finance Conference 2MiMedx Announces Agreement to Acquire Surgical Biologics 2MiMedx Announces Agreement to Acquire Surgical Biologics 3MiMedx Announces Agreement to Acquire Surgical Biologics 4MiMedx Announces Agreement to Acquire Surgical Biologics 5
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
Toothed Pituitary Rongeurs, 12 300 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: